Get the Stockscreener App
36.43
0.64%
0.23
Exelixis Inc stock is traded at $36.43, with a volume of 2.20M.
It is up +0.64% in the last 24 hours and up +9.43% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$36.20
Open:
$36.44
24h Volume:
2.20M
Relative Volume:
0.95
Market Cap:
$10.40B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
23.35
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
+2.19%
1M Performance:
+9.43%
6M Performance:
+61.19%
1Y Performance:
+62.06%
1-Day Range:
$35.91
$36.90
1-Week Range:
$35.91
$37.59
52-Week Range:
$20.02
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.43 | 10.40B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
What Makes Exelixis (EXEL) an Investment Bet? - Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Exelixis sets 2025 guidance in line with estimates - MSN
Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today? - Yahoo Finance
EXEL (Exelixis) Long-Term Debt & Capital Lease Obligation : $194 Mil (As of Sep. 2024) - GuruFocus.com
Exelixis (NASDAQ:EXEL) Given New $41.00 Price Target at Oppenheimer - MarketBeat
FY2024 EPS Estimates for Exelixis Increased by Analyst - MarketBeat
Institutional investors control 74% of Exelixis, Inc. (NASDAQ:EXEL) and were rewarded last week after stock increased 5.9% - Simply Wall St
Tallon Kerry Patrick Invests $2.62 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis price target raised to $41 from $38 at Oppenheimer - MSN
Oppenheimer bullish on Exelixis stock as cabo sales and R&D progress impress - MSN
Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip challenges - Investing.com India
Exelixis stock hits 52-week high at $36.98 amid robust growth - Investing.com Nigeria
Exelixis (NASDAQ:EXEL) Hits New 52-Week High on Analyst Upgrade - MarketBeat
15 Analysts Have This To Say About Exelixis - Benzinga
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, JMP Securities Analyst Says - MarketBeat
Burney Co. Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
FY2025 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Exelixis stock hits 52-week high at $36.98 amid robust growth By Investing.com - Investing.com South Africa
Exelixis: Truist raises price target citing increased sales potential - Investing.com
Long Term Trading Analysis for (EXEL) - Stock Traders Daily
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - MSN
FY2024 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat
Exelixis Provides Preliminary 2024 Results and Outlook for 2025 - MSN
Exelixis says no FDA AdCom for Cabometyx label expansion - MSN
Exelixis (NASDAQ:EXEL) Price Target Raised to $37.00 at Piper Sandler - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - BioSpace
Exelixis Reports Strong $1.8B Revenue for 2024, Projects Growth in 2025 with New Cancer Drug Expansion - StockTitan
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib - MSN
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza (EXEL) - Seeking Alpha
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Marketscreener.com
Exelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at Meeting - Marketscreener.com
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX - Business Wire
Range Financial Group LLC Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Given New $42.00 Price Target at Guggenheim - MarketBeat
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth? - MSN
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
Exelixis CEO to Present Corporate Strategy at J.P. Morgan Healthcare Conference 2025 - StockTitan
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How the (EXEL) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Trims Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis price target raised to $38 from $34 at RBC Capital - Yahoo Finance
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):